These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11997198

  • 21. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study.
    Rosenthal M, Moore P, Groves E, Iwan T, Schlosser LG, Dziewanowska Z, Negro-Vilar A.
    J Opioid Manag; 2007; 3(3):145-54. PubMed ID: 18027540
    [Abstract] [Full Text] [Related]

  • 22. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
    Kinzler ER, Pantaleon C, Aigner S.
    Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M, Tudor IC, Khanna S, Thipphawong J.
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of extended-release epidural morphine sulfate: pooled analysis of six clinical studies.
    Viscusi ER, Gambling DR, Hughes TL, Manvelian GZ.
    Am J Health Syst Pharm; 2009 Jun 01; 66(11):1020-30. PubMed ID: 19451613
    [Abstract] [Full Text] [Related]

  • 25. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F, Meijler WJ, Frijlink HW, Visser J, Proost JH.
    Eur J Clin Pharmacol; 2000 Jun 01; 56(3):219-23. PubMed ID: 10952476
    [Abstract] [Full Text] [Related]

  • 26. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
    Adams EH, Chwiecko P, Ace-Wagoner Y, Mangefrida B, Duerden ME, Perdikis GC, Kunkel FA, Ghalie R.
    Pain Pract; 2006 Dec 01; 6(4):254-64. PubMed ID: 17129306
    [Abstract] [Full Text] [Related]

  • 27. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N, Sun S, Johnson F, Stauffer J.
    J Pain; 2010 Apr 01; 11(4):303-11. PubMed ID: 19944650
    [Abstract] [Full Text] [Related]

  • 28. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Apr 01; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 29. Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: effect on pain, depressive symptoms, and cognition.
    Panjabi SS, Panjabi RS, Shepherd MD, Lawson KA, Johnsrud M, Barner J.
    Pain Med; 2008 Nov 01; 9(8):985-93. PubMed ID: 18694449
    [Abstract] [Full Text] [Related]

  • 30. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Dornseif BE, Damask MC.
    J Pain Symptom Manage; 2002 May 01; 23(5):355-68. PubMed ID: 12007754
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM.
    Am J Cardiol; 2006 Oct 02; 98(7A):17L-26L. PubMed ID: 17023228
    [Abstract] [Full Text] [Related]

  • 32. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
    Quigley C, Joel S, Patel N, Baksh A, Slevin M.
    Palliat Med; 2003 Mar 02; 17(2):185-90. PubMed ID: 12701850
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
    Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, Stewart JH, Mount BM.
    Cancer; 1989 Jun 01; 63(11 Suppl):2275-83. PubMed ID: 2720576
    [Abstract] [Full Text] [Related]

  • 34. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK, Ciric S, Boudriau S, Kisicki JC, Stauffer J.
    Am J Ther; 2011 Jan 01; 18(1):2-8. PubMed ID: 20864883
    [Abstract] [Full Text] [Related]

  • 35. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
    Ross EL, Hahn K.
    Int J Clin Pract; 2008 Mar 01; 62(3):471-9. PubMed ID: 18261077
    [Abstract] [Full Text] [Related]

  • 36. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
    Klepstad P, Kaasa S, Borchgrevink PC.
    Eur J Clin Pharmacol; 2000 Jan 01; 55(10):713-9. PubMed ID: 10663448
    [Abstract] [Full Text] [Related]

  • 37. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
    Wolff T, Samuelsson H, Hedner T.
    Pain; 1996 Dec 01; 68(2-3):209-16. PubMed ID: 9121807
    [Abstract] [Full Text] [Related]

  • 38. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB.
    Epilepsia; 2013 Aug 01; 54(8):1444-52. PubMed ID: 23692553
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.